Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Menu

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
Menu
My View
  • Edit
  • Add your favourite topics for quick access
Meet the Team
Ask the Analyst
Partnered Content
PDF Library
RSS Feeds
Subscribe
Advertising
Report Store
UsernamePublicRestriction
Tags:
BioPharmaceutical United States Regulation

FDA's Opioid Action Plan Could Clear Califf Nomination Roadblock

This article was originally published in The Pink Sheet Daily

  • News

Executive Summary

Policy shifts to address opioid abuse epidemic include changes to immediate-release opioid labeling, updated REMS requirements, and a new advisory committee.

Table

View full table

Advertisement

Related Content

Generics Bulletin
Final Generic Abuse-Deterrent Opioids Guidance Coming This Year
Pink Sheet
Final Generic Abuse-Deterrent Opioids Guidance Coming This Year
Pink Sheet
Gottlieb Closing In On Confirmation Despite Senate Concern On Opioids
Pink Sheet
Gottlieb Promotes 'Bottom-Up' Review To Increase FDA Efficiency, Consistency
Pink Sheet
Opioid Policy At US FDA: Gottlieb Seeks More Activist Role To Combat Abuse
Pink Sheet
Endo’s Opana ER, Generic Oxymorphone Safety Get US FDA Panel Review
Pink Sheet
FDA’s Naloxone Product Approval Standards May See Changes
Pink Sheet
Califf Nomination Suffers 'Pile On': What Can FDA Do To Break Logjam?

Topics

Related Companies

Advertisement
Tags:
BioPharmaceutical United States Regulation
UsernamePublicRestriction

Register

PS079175

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By